| Biomarker ID | 27 |
| PMID | 11500787 |
| Year | 2001 |
| Biomarker | BCL-2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in High Gleason Score |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Interleukin-7 signaling pathway,BAD phosphorylation regulation,Apoptosis intrinsic pathway,RXR/VDR pathway,Corticotropin releasing hormone pathway |
| Experiment | High (8-10) vs Low (2-4) Gleason Score |
| Type of Biomarker | Prognostic |
| Cohort | 28 patients were divided into sub groups. One with Gleason score between 8-10 (n =18) and others with Gleason Score between 2-4 (n=10) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | BCL-2 gene and it's related protiens are upregulated with more advanced prostate cancer as compared to early stage prostate cancer |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | BCL2 |